This was attributable to the action of pioglitazone in diminishing the maternal hyperinsulinaemia and increased insulin resistance that occurs during pregnancy thereby reducing the availability of metabolic substrates for foetal growth.
See tulenes pioglitasooni omadusest vähendada raseduse ajal esinevat hüperinsulineemiat ja suurenenud insuliiniresistentsust emal, vähendades seeläbi metaboolsete substraatide kasutamist loote kasvuks.